KDM1A and renal cell carcinoma: Lysine-specific demethylase 1 (LSD1) has been identified as an epigenetic target in the treatment of the disease, and a small-compound library screen revealed that several LSD1 inhibitors, including Raloxifene, showed potential therapeutic effects by effectively inhibiting LSD1 activity (IC50 = 2.08 μM) and suppressing the proliferation and migration of renal cell carcinoma cells overexpressing LSD1 (Ma et al., 2021; Song et al., 2022).